After Yungjin Pharm finally succeeded in invalidating the use patent of Abilify (aripiprazole·Korea Otsuka Pharmaceutical) after 6 years of patent dispute, other generics products of Abilify are now seeking to extend its indications.

The use patent that was in dispute had protected Abilify’s ‘bipolar disorder’ indication, due to which generic companies other than Yungjin Pharm were unable to include the indication in their Abilify generics.

According to the Ministry of Food and Drug Safety on the 16th, applications containing the 'treatment of acute manic and mixed episodes related to bipolar disorder' indication are being continuously filed for Abilify generics. Bipolar disorder, co